Jazz Pharmaceuticals plc
Research Jazz Pharmaceuticals plc (JAZZ) on Bullrun: market cap USD 14.15B, P/E 15.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJAZZ
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 14.15B
- P/E15.1
- Financial periodQ2 2026
- RevenueUSD 1.21B
- Net incomeUSD 192.80M
- Free cash flowUSD 243.40M
- Gross margin90.4%
Valuation Snapshot
latest market cap is USD 14.15B; P/E is 15.1.
Peer valuation comparison
Latest P/E is 15.06x versus a Healthcare sector median of 24.6x (38.8% below).
Latest P/E is 15.06x versus a Ireland median of 19.74x (23.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.27B | -USD 356.15M | USD 1.30B | 88.2% | -5.84 | USD 1.39B | USD 5.36B | USD 4.32B |
| FY2024 | USD 4.07B | USD 560.12M | USD 1.36B | 89.0% | 8.65 | USD 2.41B | USD 6.11B | USD 4.09B |
| FY2023 | USD 3.83B | USD 414.83M | USD 1.07B | 88.6% | 6.1 | USD 1.51B | USD 5.71B | USD 3.74B |
| FY2022 | USD 3.66B | -USD 224.06M | USD 1.24B | 85.2% | -3.58 | USD 881.48M | USD 5.72B | USD 3.09B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 14.15B | 15.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 10.44B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 7.47B | 14.2 | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.74B | 205.0 | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.03B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 7.85B | n/a | n/a | n/a |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma;
ETFs that hold Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is one of the ten largest holdings of 2 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| L&G Pharma Breakthrough UCITS ETF | 3.50% | 0.49% |
| Robeco NextGen Global Small-Cap Equity UCITS ETF USD Acc | 0.63% | 0.50% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Jazz Pharmaceuticals plc's market cap?
Jazz Pharmaceuticals plc's market capitalization is USD 14.15B.
What is Jazz Pharmaceuticals plc's P/E ratio?
Jazz Pharmaceuticals plc's price-to-earnings (P/E) ratio is 15.1.
What does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.